Journal
CANCER CELL
Volume 36, Issue 5, Pages 471-482Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2019.09.006
Keywords
-
Categories
Funding
- NIH [P30 CA008748, R01 CA236615-01, R01 CA235667]
- U.S. Department of Defense [BC132124, LC160212, CA170630, CA180889]
- Emerson Collective Cancer Research Fund
- Commonwealth Foundation for Cancer Research
- Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center
- Baker Street Foundation
Ask authors/readers for more resources
Checkpoint blockade (CPB) therapy can elicit durable clinical responses by reactivating an exhausted immune response. However, response rates remain limited, likely secondary to a lack of a tumor-reactive immune infiltrate. Chimeric antigen receptor (CAR) T cells may provide the necessary tumor-targeting immune infiltrate and a highly specific antitumor immune response. This can be further amplified by the addition of CPB agents, which serve to counteract the immune inhibitory environment undermining optimal CAR T cell efficacy. Herein, we review preclinical and clinical combination therapy with CAR T cells and CPB agents, with a focus on solid tumor malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available